Trump says he's willing to keep some portions of ACA

The 2016 U.S. presidential election is concluded, and we are left with a new leader and a country still divided. But hotel operators are taking a swing at optimism.

Despite a campaign in which he vowed to repeal the healthcare law he dubbed a “disaster,” President-elect Donald Trump now says he is willing to preserve some parts of the Affordable Care Act.

Trump and President Barack Obama discussed the subject during their meeting at the White House this week, Trump said in an interview with The Wall Street Journal, saying Obama asked him to reconsider repealing his signature domestic achievement.

Trump told the publication that he might be willing to preserve at least two provisions--the ban on denying coverage to those with pre-existing conditions and the one that allows young adults to stay on a parent’s plan for additional years.

House Speaker Paul Ryan’s proposed ACA replacement plan also suggests keeping those protections for consumers. Trump has also proposed converting Medicaid funding to block grants and selling insurance across state lines--although legal experts say the latter could be problematic.

RELATED: ACA repeal would be complex, costly

Trump said during his campaign that the healthcare law is “probably going to die of its own weight,” seizing on reports of higher premiums for ACA exchange benchmark plans as evidence of the ACA’s failure and promising to fix it.

RELATED: Financial experts split on impact of ACA repeal and replace

It was the meeting with Obama, Trump said, that led him to soften his position of seeking a full ACA repeal.

“I told him I will look at his suggestions, and out of respect, I will do that,” he told the publication. “Either Obamacare will be amended, or repealed and replaced.”

 

Suggested Articles

Blues plans have reportedly agreed to a $2.7 billion antitrust settlement.

Premera Blue Cross will pay $6.9 million to HHS over a data breach six years ago that exposed 10 million people's health information.

HHS and the FDA finalized a rule that enables states to seek approval to re-import certain drugs from Canada for a cheaper price.